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E-mail address: kay.ohlendieck@nuim.ie (K. OhlenAmyotrophic lateral sclerosis is the most common form of motor neuron disease in adult patients and
characterized by progressive paralysis. The wobbler mouse (phenotype WR, genotype wr/wr) is an estab-
lished animal model of human motor neuron disease and is characterized by a large variety of cellular
abnormalities including muscular atrophy. In analogy to recent proteomic studies of cerebrospinal fluid
and spinal cord, we have used here fluorescence difference in-gel electrophoresis to analyze global
changes in the skeletal muscle proteome fromWR versus normal mice. Relative concentrations of 21 pro-
teins were found to be increased and 3 proteins were decreased. Mass spectrometric analysis identified
these proteins to be associated with key metabolic pathways, the contractile apparatus, intermediate fil-
aments and the cellular stress response. Drastically increased levels of the glycolytic enzyme glyceralde-
hyde-3-phosphate dehydrogenase were confirmed by immunoblotting and this finding agrees with the
idea of an oxidative-to-glycolytic shift in disease-related muscular atrophy. The establishment of novel
disease-specific biomarkers of motor neuron disease might be helpful in the design of improved diagnos-
tic tools and the identification of novel therapeutic targets.
 2011 Elsevier Inc. All rights reserved.1. Introduction tory approval for the treatment of ALS, but prolongs the survivalMotor neuron diseases are a heterogeneous group of fatal neuro-
logical diseases [1]. Disorders with lower motor neuron degenera-
tion are spinal muscular atrophy, an autosomal recessive disorder
that is caused by mutations in the survival motor neuron SMN1
gene, spinal bulbar muscular atrophy, a slowly progressive adult-
onset disorder triggered by the expansion of a polyglutamine tract
in the androgen receptor gene and Charcot-Marie-Tooth disease, a
diverse group of inherited neuropathies with mutations that cause
defects in various neuronal proteins [2]. Amyotrophic lateral sclero-
sis (ALS), which can be sporadic or be of genetic origin, is the most
progressive and most frequent form of adult-onset motor neuron
disease [3]. Genetic abnormalities in ALS have been shown to occur
in the CuZn-superoxide dismutase encoding SOD1 gene and the
TDP-43 encoding TARDBP gene [3]. The degeneration of motor neu-
rons leads to contractile weakness of the limb, bulbar and respira-
tory muscle systems. Paralysis is highly progressive and is usually
fatal due to respiratory failure within 2–3 years for bulbar-onset
pathologies and within 3–5 years for limb-onset cases [4]. Cur-
rently only one drug, the glutamate antagonist riluzole, has regula-ll rights reserved.
ophoresis; ALS, amyotrophic
is; GAPDH, glyceraldehyde-3-
yHC, myosin heavy chain.
dieck).time in the treatment of adult-onset motor neuron degeneration
by only 3–4 months [5]. Since patients afflicted with ALS have a
very poor prognosis, detailed biomedical investigations into the
molecular pathogenesis of this fatal neurodegenerative disease
and an intensive search for novel therapeutic targets to treat
aggressive disorders of the neuromuscular system are warranted.
In this respect, animal models that mimic key symptoms of neu-
rodegeneration and the progressive nature of ALS may be helpful
for studying the underlying mechanisms of muscle paralysis [6].
The wobbler mouse (genotype wr/wr, phenotype WR) [7] has been
used during the last decades as an animal model of motor neuron
disease. The recessive mutation wr has been mapped to mouse
chromosome 11 [8] and was identified as a missense mutation in
the ubiquitously expressed gene Vps54 [9]. The corresponding pro-
tein, vesicular protein sorting factor VPS54, is a component of the
hetero-trimeric GARP complex involved in retrograde vesicle trans-
port to the Golgi apparatus, and thus plays a crucial part in intracel-
lular transport. Thewr allele causes a defect in spermiogenesis [10]
in addition to motoneuron degeneration. Knock out of the Vps54
gene leads to embryonic lethality [9]. Recently, it was found that
thewrmissensemutation destabilizes the VPS54 protein and there-
by leads to a reduction of its concentration [11]. Although there is
no human neurodegenerative disease known in which the gene
for VPS54 (chromosome 2p14-15) is affected [12], the WR mouse
with its rapid disease progression nevertheless represents a highly
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neuroinflammatory processes [13]. The WR mouse is also widely
employed for evaluating novel treatment options to counteract
symptoms of ALS [14].
Over the last few years, mass spectrometry-based proteomics
has been instrumental to perform global surveys of changed pro-
tein expression patterns in normal and pathological skeletal mus-
cle tissues [15]. The identification of novel disease-specific
biomarker signatures of neuromuscular diseases might be helpful
in the design of improved diagnostic tools and the establishment
of new therapeutic targets, as well as the superior monitoring of
disease progression and determination of adverse effects of exper-
imental drug treatments. The current international effort to dis-
cover reliable biomarkers of ALS [16] includes the verification of
both suitable metabolites [17] and protein factors [18]. Recent pro-
teomic profiling studies of ALS patient samples and the WR animal
model have focused on the analysis of cerebrospinal fluid [19–21]
and cervical and lumbar spinal cord [22,23], respectively. The stud-
ies on the WR mouse showed that the majority of differentially ex-
pressed proteins were related to the glutamate–glutamine cycle,
energy transduction, redox functions and astrogliosis [22], thus
confirming previous studies [24]. Here, we have applied compara-
tive proteomics to the analysis of skeletal muscle from the WR
mouse and established changes in proteins involved in metabolic
pathways, the contractile apparatus, intermediate filaments and
the cellular stress response.2. Materials and methods
2.1. Chemicals and materials
CyDye DIGE Fluor minimal dyes Cy3 and Cy5, Coomassie Blue,
ampholytes, cover fluid, acetonitrile and immobilised pH gradient
(IPG) drystrips pH 3-10 were obtained from Amersham Biosci-
ences/GE Healthcare (Little Chalfont, Buckinghamshire, UK).
Sequencing grade-modified trypsin was obtained from Promega
(Madison,WI). LC–MS Chromasolvwater and formic acidwere from
Fluka (Milwaukee,WI). Spin filterswere obtained fromFisher Scien-
tific (U.K). Protein molecular weight ladders, Laemmli-type buffer
and Bradford reagent for protein quantification were purchased
from Biorad Laboratories (Hemel-Hempstead, Hertfordshire, UK).
Protease inhibitors were from Roche Diagnostics (Mannheim,
Germany). Acrylamide stock solutions were obtained as ultrapure
Protogel from National Diagnostics (Atlanta, GA). Ultrapure lysine
for quenching the DIGE labeling reaction and all general reagents
were otained from Sigma Chemical Company (Dorset, UK).2.2. Prepartion of muscle extracts from WR and control mice
The WR mouse represents an established animal model of mo-
tor neuron disease [7]. The origin of the WR stock and breeding of
mice at the University of Bielefeld has been previously described
[8,9]. Animals were sacrificed by cervical dislocation and biochem-
ical analyses were performed with post-mortem tissue samples.
WRmutants were bred in accordance with German law on the pro-
tection of laboratory animals and approved by the local authorities.
Tibialis anterior, gastrcocnemius, soleus and vastus lateralis muscles
from 9-week old WR mice and their counter-parts from age-
matched normal C57 mice were freshly dissected and then
quick-frozen in liquid nitrogen. WR and control mice had an aver-
age body weight of 9.6 ± 1.6 g (n = 9) and 23.2 ± 3.0 g (n = 5),
respectively. The combined wet weights of the analyzed muscles
from both legs of the WR and normal mice were 124 ± 44 mg
(n = 9) and 314 ± 71 mg (n = 5), respectively. Samples were trans-
ported on dry ice and stored at 80 C prior to usage. For the prep-aration of muscle extracts, tissue specimens were ground, in the
presence of liquid nitrogen, into a fine powder using pestle and
mortar. For comparative proteomic studies, equal amounts of WR
and normal muscle tissue (100 mg wet weight) were used. Muscle
powder was suspended in 1 ml of DIGE lysis buffer and urea-solu-
ble proteins extracted as previously described in detail [25].
2.3. Fluorescence DIGE analysis of muscle extracts
A 50 mg protein sample was fluorescently labeled for each of
the protein samples being studied. Normal muscle extracts and
WR muscle extracts were each labeled with Cy3 DIGE Fluor dye
and the pooled internal standard with Cy5 DIGE Fluor dye, as pre-
viously described in detail [25]. The 2D-GE separation of fluores-
cently labeled proteins was carried out by using a total of
100 mg protein per DIGE gel. Isoelectric focusing was performed
using 24 cm strips in a IPGphor system from Amersham Biosci-
ences/GE Healthcare (Little Chalfont, Buckinghamshire, UK) using
running conditions as previously described [26]. Following first-
dimension separation, gel strips were equilibrated for 20 min in
equilibration buffer containing 100 mM dithiothreitol, followed
by 10 min of equilibration in buffer containing 250 mM ideoaceta-
mide. Using the Amersham EttanDalt–twelve system, the gel elec-
trophoretic separation of muscle-associated proteins in the second
dimension was performed with standard 12.5% (w/v) slab gels [25].
Twelve slab gels were run in parallel at 0.5 W/gel for 60 minand
then 15 W/gel until the blue dye front had disapeared from the
bottom of the gel. Fluorescently labeled proteins were visualized
using a Typhoon Trio variable mode imager. Protein expression
changes between WR and control samples were analyzed using
Progenesis SameSpots analysis software from Non Linear Dynam-
ics (Newcastle upon Tyne, UK). Prior to analysis, individual gels
were warped to a single master gel. SameSpots analysis was used
to identify proteins of interest using the following parameters:
n = 4; t-test p < 0.05; and a power value of >0.8. Proteins with a sig-
nificantly changed abundance were picked for tryptic digestion
from Coomassie Blue-stained preparative gels [25].
2.4. Mass spectrometric identification of muscle proteins and data
verification
The mass spectrometric identification of proteins of interest
was performed with 2-D protein spots from Coomassie-stained
pick gels, matched to a DIGE-labeled master gel. Standardized in-
gel tryptic digestion was used for the generation of peptides and
mass spectrometric analysis was carried out on a Model 6430 Ion
Trap LC/MS apparatus from Agilent Technologies (Santa Clara,
CA). Excision, washing, destaining and treatment with trypsin were
performed by previously optimized methods [25]. Peptide samples
were dried through vacuum centrifugation and then resuspended
in mass spectrometry-grade distilled water and 0.1% (v/v) formic
acid, spun down through spin filter and added to LC–MS viles for
identification by ion trap LC–MS analysis [25]. Separation was per-
formed with a nanoflow Agilent 1200 series system. Samples were
loaded into the enrichment at a capillary flow rate set to 2 ll/min
with a mix of 0.1% (v/v) formic acid and 50% (v/v) acetonitrile and
formic acid at a ratio of 19:1. The voltage was set to 1700 V. Data-
base searches were carried out with Mascot MS/MS Ion search
(Matrix Science, London, UK). For data verification, immunoblot-
ting was carried out as previously described in detail [26].3. Results and discussion
The underlying objective of our proteomic profiling study of the
WRmouse was the establishment of global effects of motor neuron
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Since conventional protein staining procedures have a limited dy-
namic range, we employed fluorescence DIGE analysis for the de-
tailed characterization of global changes in the urea-soluble WR
muscle proteome. The most prominent changes in gene expression
in muscles affected by motor neuron degeneration are expected to
reflect physiological denervation. In fact, an increase of the mRNA
for the a-subunit of the nicotinic acetylcholine receptor, a typical
sign of denervation, has been found in WR muscle [27]. In contrast
to myotonic mouse muscle, in which there is a shift from the dom-
inant myosin heavy chain (MyHC) isoform IIB (fast-glycolytic) to
IIX and IIA (fast-oxidative), in WR muscle there is an opposite shift
to an even higher proportion of MyHC IIB and a glycolytic pheno-
type [28]. In addition, effects related to muscular atrophy are ex-
pected. Importantly, since the WR pathology is a long-term and
continuous process, as opposed to surgical denervation, intrinsic
effects of the partial deficiency in VPS54 may cause proteome-wide
alterations in skeletal muscle.
Following differential fluorescent tagging, gel electrophoretic
separation, densitometric scanning and image analysis, 24 protein
spots were identified in WR muscle tissue that exhibit a significant
change in concentration levels. An overview of our DIGE analysis is
given in Fig. 1, which illustrates the Cy3 (WR or wild type sample)
and Cy5 (pooled standard) fluor labeling approach. A representa-
tive master gel is shown for the pH 3–10 range in Fig. 2. WR-asso-
ciated changes in the concentration of proteins included two-
dimensional spots that covered a pI-range from approximately
4.1 (Troponin C) to 8.6 (GAPDH) and ranged in molecular mass
from apparent 16 kDa (Cu/Zn superoxide dismutase) to 128 kDaCy3  WR1 Cy5 Pooled
Wobbler
Cy3
Cy3  WR2 Cy5 Pooled
Cy3  WR3 Cy5 Pooled
Cy3  WR4 Cy5 Pooled
Pooled
Cy5
Fig. 1. Two-dimensional DIGE analysis of wobbler versus normal skeletal muscle. Show
normal wild type (WT1 to WT4) mice, as well as Cy5-labeled gels containing pooled sta(Myosin binding protein C). The findings from the mass spectro-
metric identification of the 24 protein spots with a changed abun-
dance is presented in Table 1, listing protein name, accession
number, pI-value, molecular mass, number of matched peptide se-
quences, Mascot score, percentage sequence coverage, Anova score
and relative concentrations of individual proteins affected in the
WR mouse.
Identified proteins are associated with key metabolic pathways,
the contractile apparatus, intermediate filaments and the cellular
stress response. Expression levels were reduced in the case of 3
protein species and increased for 21 proteins. The mass spectro-
metric hit with the highest increase of 6.5 relative concentration
is not listed in Table 1, since this protein was only recognized by
1 peptide (MPSSMGGGGGGSPSPVELR) as histone deacetylase 5
(gi|220941642|, pI 9.07, MW 20,096, Mascot score 28, 10% cover-
age, 0.001 Anova). The second highest relative concentration was
found for the glycolytic enzyme aldolase (spot 1, Table 1), followed
by GAPDH (spot 2). These two enzymes with increased concentra-
tions, in accordance with the previously reported increase in the
MyHC isoform IIB [28] reflect a shift towards an extreme glycolytic
muscle fiber type. Other increased proteins are represented by ac-
tin (spots 4, 9, 16, 19), desmin (spots 5, 7, 11), myoglobin (spots 6,
12), myozenin (spot 8), troponin C (spot 14), actinin (spot 15), Cu/
Zn superoxide dismutase (spot 20) and fast myosin light chain 1f
(spot 21). Subtypes of creatine kinase M-type, possibly represent-
ing differently phosphorylated isoforms, showed differential
changes in a variety of protein spots. Five spots exhibited an in-
creased abundance (spots 3, 10, 13, 17, 18) and one spot a de-
creased concentration (spot 22). A decrease was shown for 2Cy3 WT1 Cy5 Pooled
Cy3 WT2 Cy5 Pooled
Cy3 WT3 Cy5 Pooled
Cy3 WT4 Cy5 Pooled
Normal
Cy3 Cy5
Pooled
n are Cy3-labeled gels of total muscle extracts from wobbler (WR1 to WR4) versus
ndards. DIGE images are shown for the pH 3–10 range.
12
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4
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Fig. 2. DIGE analysis of wobbler muscle tissue. Shown is a Cy5-labeled master gel of crude tissue extracts from WR muscle tissue covering the pH 3–10 range. Protein spots
with a changed concentration in WR preparations are marked by circles and are numbered 1–24. See Table 1 for a detailed listing of muscle-associated protein species with a
changed abundance in the WR mouse model of motor neuron disease. The pH-values of the first dimension gel system and molecular mass standards (in kDa) of the second
dimension are indicated on the top and on the left of the panels, respectively.
Table 1
DIGE-identified proteins with changed concentration levels in skeletal muscles from the wobbler mouse.
Spot
no.
Protein name Accession No. pI-
value
Molecular mass
(Da)
Peptides
matched
Mascot
score
Coverage
(%)
Anova Fold
change
1 Fructose-bisphosphate aldolase A gi|6671539| 8.31 39,795 2 79 10 0.002 4.5
2 Glyceraldehyde-3-phosphate
dehydrogenase
gi|149257623| 8.63 36,298 6 101 24 0.002 3.5
3 Creatine kinase M-type gi|6671762| 6.58 43,250 15 447 41 0.006 3.4
4 Actin, alpha-cardiac gi|387090| 5.23 42,043 12 176 32 0.005 3.4
5 Desmin gi|33563250| 5.21 53,523 25 577 57 0.003 3.3
6 Myoglobin gi|21359820| 7.07 17,117 7 249 59 0.007 3.2
7 Desmin gi|33563250| 5.21 53,523 27 475 60 0.004 3
8 Myozenin-1 gi|10946924| 8.57 31,438 6 159 25 0.008 3
9 Actin, alpha-cardiac gi|387090| 5.23 42,043 12 185 37 0.009 3
10 Creatine kinase M-type gi|6671762| 6.58 43,250 7 305 20 0.011 2.8
11 Desmin gi|33563250 5.21 53,523 21 369 49 0.008 2.6
12 Myoglobin gi|21359820| 7.07 17,117 7 274 49 0.002 2.6
13 Creatine kinase M-type gi|6671762| 6.58 43,250 5 113 14 0.008 2.3
14 Troponin C, skeletal muscle gi|6678371| 4.07 18,156 6 308 49 0.005 2.2
15 Actinin-3, alpha gi|7304855| 5.31 103,616 14 330 21 0.006 2.1
16 Actin, alpha-cardiac gi|387090| 5.32 42,048 11 89 28 0.013 1.9
17 Creatine kinase M-type gi|6671762| 6.58 43,250 6 102 18 0.007 1.8
18 Creatine kinase M-type gi|6671762| 6.58 43,246 7 295 23 0.011 1.7
19 Actin, alpha gi|49864| 5.45 38,020 8 121 30 0.01 1.7
20 Cu/Zn superoxide dismutase gi|226471| 6.03 15,926 7 156 47 0.005 1.6
21 Myosin light chain 1f gi|29789016| 4.98 20,697 13 187 61 0.013 1.4
22 Creatine kinase M-type gi|6671762| 6.58 43,250 10 152 25 0.004 0.5
23 Myosin binding protein C, fast gi|20988232| 6.02 128,115 14 170 15 0.003 0.4
24 Myosin binding protein C, fast gi|20988232| 6.02 128,100 22 344 26 0.013 0.4
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(spots 23, 24).
In order to verify key proteomic findings and to put this study
into perspective with previous analyses of WR muscle tissues, rep-
resentative immunoblots are shown in Fig. 3. The previously re-
ported decreased mRNA levels of parvalbumin [27] were shown
to correlate to a decreased protein concentration of this cytosolic
Ca2+-binding protein. The decrease in parvalbumin and increasein myoglobin on the one hand, and elevated levels of key glycolytic
enzymes on the other hand, indicate that the metabolic transfor-
mation in WR muscle is more complex than a unidirectional shift
towards an extremely glycolytic phenotype. Immunoblotting
clearly confirmed our proteomic data and showed a drastically in-
creased abundance of GAPDH and desmin in WR muscle. However,
increased levels of Cu/Zn superoxide dismutase were not signifi-
cant. Changes in the concentration of actin, troponin, actinin,
WT             WR
A Parvalbumin
WT             WR
C  GAPDH
G  Cu/Zn SOD
WT           WR
E  Desmin
WT          WR
0
50
100
*
WT      WR
0
500
1000
**
WT      WR
0
50
150
WT      WR
0
200
400
*
WT      WR
100
B
D
F
H
600
Fig. 3. Immunoblot analysis of wobbler mouse muscle. Shown are representative
immunoblots with expanded views of immuno-decorated bands labeled with
antibodies to parvalbumin (A and B), GAPDH (C and D), desmin (E and F) and Cu/Zn
superoxide dismutase (SOD) (G and H). Lanes 1 and 2 represent normal wild type
(WT) versus WR preparations, respectively. The comparative immunoblot analysis
was statistically evaluated using an unpaired Student’s t-test (n = 5; ⁄p < 0.05;
⁄⁄p < 0.01).
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atrophy-related modulations of the contractile apparatus and the
increase in desmin possibly a compensatory stabilization of the
cytoskeletal network. The drastic increase in almost all subtypes
of creatine kinase imply crucial alterations in creatine phosphate
metabolism that might be related to metabolic shifts in WR muscle
tissue. Disease-induced atrophy appears to trigger similar slow-to-
fast transition processes as previously described for disuse atrophy
[15]. Diminished neuromuscular activity or the lack of proper load-
ing has distinct effects on the integrity of the skeletal musculature.
Immobilization, disuse or denervation triggers muscular atrophy,
which clearly shows that neuromuscular innervation patterns are
directly linked to gene expression, protein abundance and isoform
patterns in skeletal muscles [29].
In analogy to the recent proteomic profiling of cerebrospinal
fluids from patients suffering from ALS and the spinal cord from
the wobbler mouse [19–23], this study describes the findings of
the MS-based proteomic survey of skeletal muscle from the WR
mouse. From the detailed analysis of the isoform patterns of the
sarcomeric MyHCs it became clear that the response of gene
expression in skeletal muscle to denervation is characteristically
different from that to hyper-excitability and muscular dystrophy
[28]. Thus, studying changes in the WR muscle proteome has the
potential to contribute crucial information on disease process dur-
ing denervation-induced muscular atrophy. Muscular atrophy is
associated with a decreased fiber size, a drastic loss in muscle tis-sue mass and a decrease in isometric contractile force. In general,
muscular atrophy is observed in skeletal muscles under conditions
of microgravity and following extended periods of bed rest, trau-
matic injury to motor units or pathological damage to motor neu-
rons [29]. Insufficient loading, denervation or disuse is usually
associated with slow-to-fast muscle transitions, which has been
confirmed by recent MS-based proteomic studies [30–35]. The pro-
teomic profiling of muscular atrophy has revealed an increase in
key enzymes of the glycolytic pathway and a concomitant decrease
in slow contractile proteins, such as the cardiac isoform of myosin
heavy chain, slow troponin T and slow myosin light chain [30–35].
In analogy, the proteomic analysis of the WR mouse, which repre-
sents an animal model of disease-induced muscular atrophy,
showed an increase in the abundance of key glycolytic enzymes.
Thus, the proteomic analysis presented here supports the general
idea of disuse- and atrophy-associated oxidative-to-glycolytic
transformation processes. In the long-term, the newly identified
global changes in the soluble skeletal muscle proteome may be
useful candidates for the establishment of a biomarker signature
of motor neuron disease [18].
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